Nucala 100 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FHNR1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,318
Award facts
- Contract value 100% obligated
- $19,318.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $19,318.30 to DMS Pharmaceutical Group Inc. for NUCALA 100 mg/mL syringes on December 1, 2025, with an ultimate completion date of December 2, 2025. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order operates under a firm fixed-price contract structure and will be performed at the vendor's Park Ridge, Illinois location.
This award is issued as a delivery order under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), which was established on November 13, 2025, with a $499.999 billion ceiling and completion date of December 31, 2036. The PPV-G GEN V represents a critical component of the Department of Defense's broader $30.3 billion pharmaceutical supply initiative, positioning DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables to support military healthcare facilities worldwide. NUCALA, an immunosuppressant biologic agent, represents one of the specialized pharmaceutical products within the company's established portfolio supporting DoD medical supply requirements.
Quick answers
Who was awarded contract SPE2DR26FHNR1?
SPE2DR26FHNR1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DR26FHNR1 worth?
The government has obligated $19,318 on SPE2DR26FHNR1.
Is contract SPE2DR26FHNR1 an order under another contract?
Yes. SPE2DR26FHNR1 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.
Was contract SPE2DR26FHNR1 competed?
The extent of competition for SPE2DR26FHNR1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award